APVO-711

N/A

Report date: 2024/04/11 15:11:32

Base Information

Drug NameAPVO-711

Drug Alias NameAPVO711APVO-711

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsProgrammed cell death protein 1 inhibitorsT lymphocytes stimulants +[4]

TargetsProgrammed cell death protein 1Tumor necrosis factor receptor superfamily member 5

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAptevo Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAptevo Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A